A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Roni Tamari; Sheetal Ramnat Sheetal; Deborah Kuk; Esperanza B. Papadopoulos; Ann A. Jakubowski; Farid Boulad; Trudy N. Small; Nancy A. Kernan; Miguel A Perales; Guenther Koehne; Doris M Ponce; Sean Devlin; Jenna D Goldberg; James W. Young; Sergio A Giralt; Richard J. O'Reilly; Hugo R Castro-Malaspina

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Roni Tamari, Sheetal Ramnat Sheetal, Deborah Kuk, Esperanza B. Papadopoulos, Ann A. Jakubowski, Farid Boulad, Trudy N. Small, Nancy A. Kernan, Miguel A Perales, Guenther Koehne, Doris M Ponce, Sean Devlin, Jenna D Goldberg, James W. Young, Sergio A Giralt, Richard J. O'Reilly, Hugo R Castro-Malaspina

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 16 2012
Event	Blood - Duration: Jan 1 2020 → …

Conference

Conference	Blood
Period	1/1/20 → …

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Cite this

Tamari, R., Sheetal, S. R., Kuk, D., Papadopoulos, E. B., Jakubowski, A. A., Boulad, F., Small, T. N., Kernan, N. A., Perales, M. A., Koehne, G., Ponce, D. M., Devlin, S., Goldberg, J. D., Young, J. W., Giralt, S. A., O'Reilly, R. J., & Castro-Malaspina, H. R. (2012). A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS. Blood.

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS. / Tamari, Roni; Sheetal, Sheetal Ramnat; Kuk, Deborah et al.
2012. Blood.

Research output: Contribution to conference › Presentation

Tamari, R, Sheetal, SR, Kuk, D, Papadopoulos, EB, Jakubowski, AA, Boulad, F, Small, TN, Kernan, NA, Perales, MA, Koehne, G, Ponce, DM, Devlin, S, Goldberg, JD, Young, JW, Giralt, SA, O'Reilly, RJ & Castro-Malaspina, HR 2012, 'A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS', Blood, 1/1/20.

@conference{d31640fd51aa43b39b4db892bc806df7,

title = "A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS",

author = "Roni Tamari and Sheetal, \{Sheetal Ramnat\} and Deborah Kuk and Papadopoulos, \{Esperanza B.\} and Jakubowski, \{Ann A.\} and Farid Boulad and Small, \{Trudy N.\} and Kernan, \{Nancy A.\} and Perales, \{Miguel A\} and Guenther Koehne and Ponce, \{Doris M\} and Sean Devlin and Goldberg, \{Jenna D\} and Young, \{James W.\} and Giralt, \{Sergio A\} and O'Reilly, \{Richard J.\} and Castro-Malaspina, \{Hugo R\}",

note = "Abstract 1935 Introduction: The success of allogeneic HSCT in the treatment of advanced MDS has been limited by high incidence of relapse and transplant-related mortality (TRM). The main complications contributing to TRM are graft-vs-host disease (GvHD) and infections. Although T cell depletion has successfully reduced the incidence of GvHD, slow immune reconstitution and high rate of infections have compromised its full potential.; Blood ; Conference date: 01-01-2020",

year = "2012",

month = nov,

day = "16",

language = "American English",

}

TY - CONF

T1 - A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

AU - Tamari, Roni

AU - Sheetal, Sheetal Ramnat

AU - Kuk, Deborah

AU - Papadopoulos, Esperanza B.

AU - Jakubowski, Ann A.

AU - Boulad, Farid

AU - Small, Trudy N.

AU - Kernan, Nancy A.

AU - Perales, Miguel A

AU - Koehne, Guenther

AU - Ponce, Doris M

AU - Devlin, Sean

AU - Goldberg, Jenna D

AU - Young, James W.

AU - Giralt, Sergio A

AU - O'Reilly, Richard J.

AU - Castro-Malaspina, Hugo R

N1 - Abstract 1935 Introduction: The success of allogeneic HSCT in the treatment of advanced MDS has been limited by high incidence of relapse and transplant-related mortality (TRM). The main complications contributing to TRM are graft-vs-host disease (GvHD) and infections. Although T cell depletion has successfully reduced the incidence of GvHD, slow immune reconstitution and high rate of infections have compromised its full potential.

PY - 2012/11/16

Y1 - 2012/11/16

UR - http://www.bloodjournal.org/content/120/21/1935?sso-checked=true

M3 - Presentation

T2 - Blood

Y2 - 1 January 2020

ER -

A Phase II Trial of Peri-Transplant Palifermin with Busulfan, Melphalan and Fludarabine Followed by T-Cell Depleted Hematopoietic Stem Cell Transplants in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved From MDS

Conference

Disciplines

Other files and links

Cite this